Current Immunoassays and Detection of Antibodies Elicited by Omicron SARS-CoV-2 Infection

Overview

Journal J Med Virol

Specialty Microbiology

Date 2022 Oct 8

PMID 36207814

Authors

Marion Migueres

Sabine Chapuy-Regaud

Marcel Miedouge

Thibaut Jamme

Catherine Lougarre

Isabelle Da Silva

Melanie Pucelle

Laetitia Staes

Marion Porcheron

Chloe Dimeglio

Jacques Izopet

Affiliations

Soon will be listed here.

Abstract

The present study aimed to determine whether current commercial immunoassays are adequate for detecting anti-Omicron antibodies. We analyzed the anti-SARS-CoV-2 antibody response of 23 unvaccinated individuals 1-2 months after an Omicron infection. All blood samples were tested with a live virus neutralization assay using a clinical Omicron BA.1 strain and four commercial SARS-CoV-2 immunoassays. We assessed three anti-Spike immunoassays (SARS-CoV-2 IgG II Quant [Abbott S], Wantaï anti-SARS-CoV-2 antibody ELISA [Wantaï], Elecsys Anti-SARS-CoV-2 S assay [Roche]) and one anti-Nucleocapsid immunoassay (Abbott SARS-CoV-2 IgG assay [Abbott N]). Omicron neutralizing antibodies were detected in all samples with the live virus neutralization assay. The detection rate of the Abbott S, Wantai, Roche, and Abbott N immunoassays were 65.2%, 69.6%, 86.9%, and 91.3%, respectively. The sensitivities of Abbott S and Wantai immunoassays were significantly lower than that of the live virus neutralization assay (p = 0.004, p = 0.009; Fisher's exact test). Antibody concentrations obtained with anti-S immunoassays were correlated with Omicron neutralizing antibody concentrations. These data provide clinical evidence of the loss of performance of some commercial immunoassays to detect antibodies elicited by Omicron infections. It highlights the need to optimize these assays by adapting antigens to the circulating SARS-CoV-2 strains.

Citing Articles

A novel method for detecting SARS-CoV-2 IgM and IgG based on the gold immune chromatography assay.

Yao X, Xu H, Du Q, Lu X, Wang Q Sci Rep. 2025; 15(1):4995.

PMID: 39929938 PMC: 11811196. DOI: 10.1038/s41598-025-89012-1.

Anti-SARS-CoV-2 serology based on ancestral RBD antigens does not correlate with the presence of neutralizing antibodies against Omicron variants.

Depery L, Bally I, Amen A, Nemoz B, Buisson M, Grossi L Microbiol Spectr. 2024; 13(1):e0156824.

PMID: 39565133 PMC: 11705886. DOI: 10.1128/spectrum.01568-24.

On-site detection of infectious disease based on CaCO-based magnetic micromotor integrated with graphene field effect transistor.

Liu Y, Wang M, Chen F, Zhang Y, Hai W Mikrochim Acta. 2024; 191(5):257.

PMID: 38600405 DOI: 10.1007/s00604-024-06345-w.

Testing for SARS-CoV-2: lessons learned and current use cases.

Theel E, Kirby J, Pollock N Clin Microbiol Rev. 2024; 37(2):e0007223.

PMID: 38488364 PMC: 11237512. DOI: 10.1128/cmr.00072-23.

Clinical and immunological outcomes of SARS-CoV-2-infected vaccine responders, vaccine non-responders, and unvaccinated patients evaluated for neutralizing monoclonal antibody treatment at a single German tertiary care center: a retrospective cohort....

Triebelhorn J, Schneider J, Spinner C, Iakoubov R, Voit F, Wagner L Infection. 2024; 52(3):1143-1151.

PMID: 38305828 PMC: 11143028. DOI: 10.1007/s15010-023-02171-z.

References

Riester E, Findeisen P, Hegel J, Kabesch M, Ambrosch A, Rank C . Performance evaluation of the Roche Elecsys Anti-SARS-CoV-2 S immunoassay. J Virol Methods. 2021; 297:114271. PMC: 8393518. DOI: 10.1016/j.jviromet.2021.114271. View

Macedo A, Prestes G, Colonetti T, Rodrigues Candido A, Uggioni M, Gomes A . A systematic review and meta-analysis of the accuracy of SARS-COV-2 IGM and IGG tests in individuals with COVID-19. J Clin Virol. 2022; 148:105121. PMC: 8863416. DOI: 10.1016/j.jcv.2022.105121. View

Chapuy-Regaud S, Miedouge M, Abravanel F, Da Silva I, Porcheron M, Fillaux J . Evaluation of Three Quantitative Anti-SARS-CoV-2 Antibody Immunoassays. Microbiol Spectr. 2021; 9(3):e0137621. PMC: 8694121. DOI: 10.1128/spectrum.01376-21. View

Manalac J, Yee J, Calayag K, Nguyen L, Patel P, Zhou D . Evaluation of Abbott anti-SARS-CoV-2 CMIA IgG and Euroimmun ELISA IgG/IgA assays in a clinical lab. Clin Chim Acta. 2020; 510:687-690. PMC: 7476889. DOI: 10.1016/j.cca.2020.09.002. View

Dimeglio C, Herin F, Da-Silva I, Porcheron M, Martin-Blondel G, Chapuy-Regaud S . Post-Vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Kinetics and Protection Duration. Clin Infect Dis. 2021; 75(1):e924-e925. PMC: 8690160. DOI: 10.1093/cid/ciab984. View

Dimeglio C, Herin F, Da-Silva I, Gernigon C, Porcheron M, Chapuy-Regaud S . Decreased Efficiency of Neutralizing Antibodies from Previously Infected or Vaccinated Individuals against the B.1.617.2 (Delta) SARS-CoV-2 Variant. Microbiol Spectr. 2022; 10(4):e0270621. PMC: 9430143. DOI: 10.1128/spectrum.02706-21. View

Cohen C, Kleynhans J, von Gottberg A, McMorrow M, Wolter N, Bhiman J . SARS-CoV-2 incidence, transmission, and reinfection in a rural and an urban setting: results of the PHIRST-C cohort study, South Africa, 2020-21. Lancet Infect Dis. 2022; 22(6):821-834. PMC: 8920516. DOI: 10.1016/S1473-3099(22)00069-X. View

Deshpande P, Abraham I, Pitamberwale A, Dhote R . Review of Clinical Performance of Serology Based Commercial Diagnostic Assays for Detection of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies. Viral Immunol. 2022; 35(2):82-111. DOI: 10.1089/vim.2020.0313. View

Migueres M, Dimeglio C, Mansuy J, Abravanel F, Raymond S, Latour J . Influence of Nasopharyngeal Viral Load on the Spread of the Omicron BA.2 Variant. Clin Infect Dis. 2022; 76(3):e514-e517. DOI: 10.1093/cid/ciac563. View

10.

Servellita V, Syed A, Morris M, Brazer N, Saldhi P, Garcia-Knight M . Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants. Cell. 2022; 185(9):1539-1548.e5. PMC: 8930394. DOI: 10.1016/j.cell.2022.03.019. View

11.

Migueres M, Lhomme S, Tremeaux P, Dimeglio C, Ranger N, Latour J . Evaluation of two RT-PCR screening assays for identifying SARS-CoV-2 variants. J Clin Virol. 2021; 143:104969. PMC: 8411575. DOI: 10.1016/j.jcv.2021.104969. View

12.

Dimeglio C, Herin F, Miedouge M, Cambus J, Abravanel F, Mansuy J . Screening for SARS-CoV-2 antibodies among healthcare workers in a university hospital in southern France. J Infect. 2020; 82(1):e29-e32. PMC: 7526656. DOI: 10.1016/j.jinf.2020.09.035. View

13.

Migueres M, Chapuy-Regaud S, Miedouge M, Jamme T, Lougarre C, Da Silva I . Current immunoassays and detection of antibodies elicited by Omicron SARS-CoV-2 infection. J Med Virol. 2022; 95(1):e28200. PMC: 9874650. DOI: 10.1002/jmv.28200. View

14.

Montesinos I, Dahma H, Wolff F, Dauby N, Delaunoy S, Wuyts M . Neutralizing antibody responses following natural SARS-CoV-2 infection: Dynamics and correlation with commercial serologic tests. J Clin Virol. 2021; 144:104988. PMC: 8479371. DOI: 10.1016/j.jcv.2021.104988. View

15.

He C, He X, Yang J, Lei H, Hong W, Song X . Spike protein of SARS-CoV-2 Omicron (B.1.1.529) variant have a reduced ability to induce the immune response. Signal Transduct Target Ther. 2022; 7(1):119. PMC: 8994023. DOI: 10.1038/s41392-022-00980-6. View

16.

Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y . Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019. Clin Infect Dis. 2020; 71(16):2027-2034. PMC: 7184337. DOI: 10.1093/cid/ciaa344. View

17.

Vacharathit V, Aiewsakun P, Manopwisedjaroen S, Srisaowakarn C, Laopanupong T, Ludowyke N . CoronaVac induces lower neutralising activity against variants of concern than natural infection. Lancet Infect Dis. 2021; 21(10):1352-1354. PMC: 8389976. DOI: 10.1016/S1473-3099(21)00568-5. View